US5221607A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Assays and reagents for amyloid deposition
Assignee: Scios LLC
•
Filing: 1991-10-29
•
Granted: 1993-06-22
•
Expires: 2011-10-29
Abstract
Abstract The present invention provides an in vitro tissue culture-based assay for amyloid deposition specific for Alzheimer's disease which is suitable for routine drug screening analysis. Immunological diagnostic reagents for Alzheimer's disease are also provided.
Inventors
- 👤 Barbara Cordell
- 👤 David Wolf
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 16:01
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4711; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/5005; G01N33/5008; G01N33/68; G01N33/6893; G01N33/6896; G01N2800/00; G01N2800/28; G01N2800/2814; G01N2800/2821; Y; Y10; Y10S; Y10S436/00; Y10S436/811; Y10S530/00; Y10S530/806; Y10S530/827; Y10S530/839
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
88 words
A method of screening agents capable of affecting the amount of preamyloid deposits, comprising: a) culturing a cell line transfected with a DNA sequence which encodes and intracellularly expresses the following polypeptide: ##STR3## the DNA sequence expressing a β-amyloid protein as an insoluble, preamyloid aggregate inside the cell which preamyloid aggregate is not detected with Congo red stain; b) combining a known quantity of the agent to be tested with the cell culture; and c) monitoring the combination to determine the effect on the amount of preamyloid aggregate.
Claim 2
Independent Claim
88 words
A method of screening agents capable of affecting the amount of preamyloid deposits, comprising: a) culturing a cell line transfected with a DNA sequence which encodes and intracellularly expresses the following polypeptide: ##STR3## the DNA sequence expressing a β-amyloid protein as an insoluble, preamyloid aggregate inside the cell which preamyloid aggregate is not detected with Congo red stain; b) combining a known quantity of the agent to be tested with the cell culture; and c) monitoring the combination to determine the effect on the amount of preamyloid aggregate.
Claim 3
Dependent Claim
18 words
The method of claim 1 wherein the DNA sequence encodes the first 42 amino acids of said polypeptide.
Claim 4
Dependent Claim
17 words
The method of claim 1 wherein the DNA sequence encodes all 99 amino acids of said polypeptide.
Claim 5
Dependent Claim
19 words
The method of claim 1 wherein the cell lines are transfected with the DNA sequence using recombinant vaccinia virus.
Claim 6
Dependent Claim
15 words
The method of claim 1 wherein the cell lines are derived from mammalian host cells.
Claim 7
Dependent Claim
30 words
The method of claim 1 wherein the agent to be tested is introduced during the growth phase of the cell culture to determine whether the agent inhibits preamyloid aggregate formation.
Claim 8
Dependent Claim
26 words
The method of claim 1 wherein the agent to be tested is added to the preamyloid aggregate to determine whether the agent dissolves the preamyloid aggregate.
References Cited (Backward Citations)
US4264729A
Cited
US4603112A
Cited
US4666829A
Cited
US4912206A
Cited
US4919915A
Cited
EP0304013A2
Cited
WO1989006689A1
Cited
WO1989006693A1
Cited
WO1989007657A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-06-21 | 1996-12-21 | 1997-06-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-06-21 | 2000-12-21 | 2001-06-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-06-21 | 2004-12-21 | 2005-06-22 | $7700.00 | Window Closed / Lapsed |